Finasteride, a common hormone-blocking drug, reduces men’s risk of getting prostate cancer without increasing their risk of dying from the disease, according to long-term follow-up data.
As the debate around Galleri, the multi-cancer detection test developed by GRAIL Inc., rages on, fueled most recently by the full-steam-ahead support it has received from regulatory and legislative bodies, NCI Director Anthony Letai has turned his attention to the available data.
